‘HPP is an organised, experienced team with an unprecedented focus on communication and collaboration. They coordinate activity with a flexible approach to the fluctuations in needs of project tasks and participants, while maintaining momentum toward the objective at hand. They are detail-oriented and timely with responses, and they truly comprehend the perspectives of stakeholders with whom they work in any given aspect of health policy research and strategy.’
HPP co-authored a lay summary of findings from the International Brain Tumour Alliance and Society for Neuro-Oncology survey on how COVID-19 has affected brain tumour patients and carers around the world.
The lack of evidence around medication use in pregnancy leaves many women with chronic diseases facing difficult choices about whether, and how, to start a family.
In June 2020, HPP developed a think piece exploring areas in which gaps exposed by the COVID-19 pandemic could be addressed to help build more robust health and social care systems.
Osteoporosis – a chronic disease that weakens bones and leaves people at risk of a fragility fracture – is expected to become more common as populations age across Europe.
Radioligand therapy is an innovative approach to treating certain types of cancer by delivering radiation to specifically targeted cancer cells, with a minimal effect on healthy cells.
Multiple sclerosis is a neurological disorder that places unique challenges on health and social care systems, which must work together to ensure the needs and goals of every person with MS are met.
Programmes that support immunisation across the life course can improve population health and promote health system sustainability. International examples of best practice offer valuable lessons.
The progressive form of non‑alcoholic fatty liver disease, known as non‑alcoholic steatohepatitis (NASH), is a growing concern as the global prevalence of obesity and type 2 diabetes continues to rise.
Genetic mutations in the BRCA1 and BRCA2 genes are associated with a significant risk of developing breast cancer, but many people who may carry these mutations cannot access genetic testing.
Atrial fibrillation is a common condition and leading cause of stroke, yet is widely under-recognised and people across Europe face significant inequalities in access to detection and treatment.